Welcome to the Lee laboratory. Our aim is to identify molecular drivers and biological properties of prostate and bladder cancer that may be exploited for the development of new and effective treatments. In our research we employ cutting-edge technologies including mouse and human epithelial transformation systems; functional genomics; multi-omic data integration; high-throughput screening; small molecule drug discovery; and immuno-oncology to develop new approaches to stratify and treat prostate and bladder cancer.
Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. DeLucia DC, Cardillo TM, Ang LS, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, Gil da Costa RM, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK.
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON.
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.
Gerardo Javier Sanchez joins the lab as a permanent graduate student enrolled in the UW M3D graduate program. Welcome!
The Lee Lab is awarded a Bladder Cancer Advocacy Network (BCAN) 2021 Bladder Cancer Research Innovation Award to support research on understanding determinants of variant histologies of bladder cancer initiation/maintenance and their response to chemoimmunotherapy.
Vipul Bhatia joins the lab as a post-doctoral fellow. Welcome!